Patent Tracker

Subject Matter

Aerosols of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof are provided which are useful for administration to a patient through an inhalation route. The aerosols have aerosol particle mass densities in the range of about 0.5 mg/l to about 12.5 mg/l.

Subject Matter

Methods of treating PTSD and psychiatric disorders using xenon and/or argon, in combination with psychotherapy, and in some embodiments in combination with MDMA.

Subject Matter

The present disclosure describes compounds and pharmaceutically acceptable salts thereof and compositions and formulations comprising the same that are useful in methods of treating dyskinesia or related disorders, and methods for treating dyskinesia or related disorders.

Subject Matter

The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.

Subject Matter

Provided are deuterated analogs of MDMA, including deuterated empathogens. In some embodiments, such compounds are monoamine releasers or inhibit monoamine transporters. In some aspects, features of the compounds provide stability, such as metabolic stability, and efficacy. Also provided are methods for the preparation of deuterated empathogens and pharmaceutical compositions comprising the same. Methods of using the deuterated empathogens, alone or in combination with other therapeutic agents, are provided. In some embodiments, deuterated empathogens are used to treat CNS disorders, such as mental health conditions and neurodegenerative disorders.

Subject Matter

Improved N,N-dimethyltryptamine prodrugs and conjugates

Subject Matter

The present invention relates to an improved method of synthesis of 1-(3′,4′-methylenedioxyphenyl)-2-(methylamino)propane (MDMA) that is of sufficient purity that it can be used for pharmaceutical applications. In particular the present invention provides a method of synthesising MDMA comprising the steps of (a) condensation of piperonal and nitroethane in the presence of a catalysing base to form 1-(3′,4′-methylenedioxyphenyl)-2-nitroprop-1-ene (MDP-2-nitropropene), (b) oxidative hydrolysis of MDP-2-nitropropene to form 1-(3′,4’methylenedioxyphenyl)-propan-2-one (MDP2P), and (c) reductive amination of MDP2P to 1-(3′,4′-methylenedioxyphenyl)-2-(methylamino)propane (MDMA).

Subject Matter

A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt.

Subject Matter

Provided herein are methods for the safe use of compositions comprising psilocin and prodrugs of psilocin for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.

Subject Matter

A method and system for propagating fungi or other filamentous organisms. Liquid media, inoculum and an envelope system in a vessel are agitated to distribute nutrientswithin the liquid media, and to remove waste from the liquid media. Agitation of the liquid media results in shear. The envelope system provides a physical barrier between the filamentous organism and the liquid media, mitigating shear forces on filamentous organism within the envelop system. The barrier may include walls of one or more propagation envelopes making up the envelope system. Inside each propagation envelope is a propagation chamber in fluid communication with liquid media in the vessel through an aperture in the propagation envelope. The aperture may include a valve or other feature to mitigate flow of mycelia, other filamentous propagating material, or other biological structures out of the propagation chambers, facilitating propagation of the filamentous organism within the propagation chambers.